Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$8.08 USD

8.08
260,975

+0.29 (3.72%)

Updated Sep 19, 2024 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

by Zacks Equity Research

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

by Zacks Equity Research

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

by Zacks Equity Research

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study

by Zacks Equity Research

BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.

Bayer Initiates Late-Stage Study on Investigational NSCLC Drug

by Zacks Equity Research

BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.

Bayer, NextRNA to Develop Therapeutics Targeting Oncology

by Zacks Equity Research

BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

by Zacks Equity Research

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug

by Zacks Equity Research

Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

by Zacks Equity Research

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.

Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales

by Zacks Equity Research

Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

by Zacks Equity Research

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.

Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised

by Zacks Equity Research

Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.

Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised

by Zacks Equity Research

Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.

Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study

by Zacks Equity Research

Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

by Zacks Equity Research

ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.

Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug

by Zacks Equity Research

Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

Bayer's (BAYRY) AskBio Advances Parkinson Disease Study

by Zacks Equity Research

Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.

Regeneron (REGN) Announces Positive Data on Oncology Candidate

by Zacks Equity Research

Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates

by Kinjel Shah

Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

by Zacks Equity Research

Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

by Zacks Equity Research

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

by Zacks Equity Research

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.